Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Patient Experience Interviews with a Novel Treatment Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

Carlos De Castro, Phillip Scheinberg, Bing Han, Susan Vallow, Georgina Bermann, Marion Dahlke, Zhixin Wang, Rakesh Kumar, Gavin Dickie, Caitlyn Lowe, Kaelyn Rupinski, Amber Nieves, Regis Peffault De Latour

Blood (2023) 142 (Supplement 1): 7339.

https://doi.org/10.1182/blood-2023-186840

Published: 2023

Journal Articles

Patient-Reported Improvements in Fatigue and Health-Related Quality of Life in the Phase 3 Studies Apply-PNH and Appoint-PNH Evaluating the Use of Iptacopan in C5 Inhibitor-Treated and Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Antonio M Risitano, Carlos M de Castro, Bing Han, Austin Kulasekararaj, Jaroslaw P. Maciejewski, Phillip Scheinberg, Yasutaka Ueda, Susan Vallow, Georgina Bermann, Marion Dahlke, Rakesh Kumar, Regis Peffault de Latour

Blood (2023) 142 (Supplement 1): 487.

https://doi.org/10.1182/blood-2023-179035

Published: 2023

Journal Articles

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Blood (2023) 142 (Supplement 1): 571.

https://doi.org/10.1182/blood-2023-180780

Published: 2023

Journal Articles

Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

Blood (2022) 140 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2022-171469

Published: 2022

Journal Articles

IL-1 Via IRAK1/4 Sustains Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse

Tzu-Chieh Ho, Hiroki Kawano, Mark W. LaMere, Naxin Guo, Yu-Chiao Chiu, Jian Wang, Craig T. Jordan, Nikolay V. Dokholyan, Laura M. Calvi, Rakesh Kumar Singh, Michael W. Becker

Blood (2021) 138 (Supplement 1): 1175.

https://doi.org/10.1182/blood-2021-149903

Published: 2021

Journal Articles

Related and Unrelated Donor Transplantation for β Thalassemia Major: Results of an International Survey

Blood (2018) 132 (Supplement 1): 308.

https://doi.org/10.1182/blood-2018-99-111152

Published: 2018

Journal Articles

Comparison of Hospital Costs and in-Hospital Outcomes of Patients Admitted with Sepsis with and without Non Hodgkin Lymphoma

Karan Jatwani, MBBS, Shraddha Jatwani, MBBS, MD, Karan Chugh, MBBS, MD, Sridevi Rajeeve, MD, Rakesh Kumar Sharma, MBBS, MD, Stuthi Perimbeti, MD MPH, Vivek Suresh Modi, MBBS, Siva Krishna Mannem, MBBS

Blood (2018) 132 (Supplement 1): 5817.

https://doi.org/10.1182/blood-2018-99-120220

Published: 2018

Journal Articles

Opportunistic Infections, Is Non Hodgkin Lymphoma One of the Risk Factors for Mortality?

Karan Jatwani, MBBS, Shraddha Jatwani, MBBS, MD, Sridevi Rajeeve, MD, Karan Chugh, MBBS, MD, Rakesh Kumar Sharma, MBBS, MD, Stuthi Perimbeti, MD MPH, Vivek Suresh Modi, MBBS, Siva Krishna Mannem, MBBS

Blood (2018) 132 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2018-99-120214

Published: 2018

Journal Articles

Bortezomib, Lenalidomide and Low-Dose Dexamethasone (VRD) Versus Lenalidomide and Low-Dose Dexamethasone (Ld) for Newly-Diagnosed Multiple Myeloma- a Randomized Phase III Study

Anjali Mookerjee, MBBS, Ritu Gupta, Shivali Jasrotia, PhD, Ranjit Sahoo, Rakesh Kumar, Sanjay Thulkar, Om Dutt Sharma, Lalit Kumar

Blood (2017) 130 (Supplement 1): 906.

https://doi.org/10.1182/blood.V130.Suppl_1.906.906

Published: 2017

Journal Articles

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Andrew Spencer, Sung-Soo Yoon, Simon J. Harrison, Shannon R. Morris, Deborah A. Smith, Richard A. Brigandi, Jennifer Gauvin, Rakesh Kumar, Joanna B. Opalinska, Christine Chen

Blood (2014) 124 (14): 2190–2195.

https://doi.org/10.1182/blood-2014-03-559963

Published: 2014

Includes: Supplemental data

Journal Articles

A Novel Function of MLL in the S Phase Checkpoint: MLL Is Phosphorylated by ATR Upon DNA Damage, Which Blocks Its Degradation by the SCF skp2 Proteasome, Leading to Its Accumulation That Directly Inhibits DNA Replication.

Han Liu, Shugaku Takeda, Rakesh Kumar, Todd Westergard, Tej Pandita, Emily Cheng, MD, PhD, James J.-D. Hsieh, MD, PhD

Blood (2009) 114 (22): 450.

https://doi.org/10.1182/blood.V114.22.450.450

Published: 2009

Journal Articles

AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines

Dana S. Levy, Jason A. Kahana, Rakesh Kumar

Blood (2009) 113 (8): 1723–1729.

https://doi.org/10.1182/blood-2008-02-137737

Published: 2009

Includes: Supplemental data

Journal Articles

The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma.

Klaus Podar, MD, MSc, PhD, Giovanni Tonon, MD, PhD, Martin Sattler, PhD, Yu-Tzu Tai, PhD, Steven LeGouill, MD, Hiroshi Yasui, MD, PhD, Kenji Ishitsuka, MD, PhD, Rakesh Kumar, PhD, Lini N. Pandite, MD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 5003.

https://doi.org/10.1182/blood.V108.11.5003.5003

Published: 2006

Journal Articles

Impact of FDG-PET Imaging Versus Conventional Staging Modalities on Staging and Treatment Decisions in Large B-Cell, Follicular, and Hodgkin’s Lymphomas.

Ivan Maillard, MDPhD, Rebecca L. Elstrom, MD, Rakesh Kumar, MD, Murat F. Bozkurt, MD, Srikant Sankaran, MD, Liang Guan, MD, Hongming Zhuang, MDPhD, David Herman, Lisa Downs, Abass Alavi, MD, Stephen J. Schuster, MD

Blood (2004) 104 (11): 4565.

https://doi.org/10.1182/blood.V104.11.4565.4565

Published: 2004

Journal Articles

Effects of the Indazolylpyrimidine GW786034 on Angiogenesis and MM Cell Growth: Therapeutic Implications.

Klaus Podar, MD, PhD, Melissa Simoncini, BS, Steven Le Gouill, MD, Yu-Tzu Tai, PhD, Shaji Kumar, MD, Pierfrancesco Tassone, MD, Laurence P. Catley, MD, Lini N. Pandite, MD, Rakesh Kumar, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, JD, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2452.

https://doi.org/10.1182/blood.V104.11.2452.2452

Published: 2004

Journal Articles

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

Klaus Podar, Laurence P. Catley, Yu-Tzu Tai, Reshma Shringarpure, Pedro Carvalho, Toshiaki Hayashi, Renate Burger, Robert L. Schlossman, Paul G. Richardson, Lini N. Pandite, Rakesh Kumar, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson

Blood (2004) 103 (9): 3474–3479.

https://doi.org/10.1182/blood-2003-10-3527

Published: 2004

Journal Articles

Telomerase Regulation, Cell Cycle, and Telomere Stability in Primitive Hematopoietic Cells

Monika Engelhardt, Rakesh Kumar, Juan Albanell, Ruth Pettengell, Wei Han, Malcolm A.S. Moore

Blood (1997) 90 (1): 182–193.

https://doi.org/10.1182/blood.V90.1.182

Published: 1997

NARROW

Patient Experience Interviews with a Novel Treatment Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

Patient-Reported Improvements in Fatigue and Health-Related Quality of Life in the Phase 3 Studies Apply-PNH and Appoint-PNH Evaluating the Use of Iptacopan in C5 Inhibitor-Treated and Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

IL-1 Via IRAK1/4 Sustains Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse

Related and Unrelated Donor Transplantation for β Thalassemia Major: Results of an International Survey

Comparison of Hospital Costs and in-Hospital Outcomes of Patients Admitted with Sepsis with and without Non Hodgkin Lymphoma

Opportunistic Infections, Is Non Hodgkin Lymphoma One of the Risk Factors for Mortality?

Bortezomib, Lenalidomide and Low-Dose Dexamethasone (VRD) Versus Lenalidomide and Low-Dose Dexamethasone (Ld) for Newly-Diagnosed Multiple Myeloma- a Randomized Phase III Study

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

A Novel Function of MLL in the S Phase Checkpoint: MLL Is Phosphorylated by ATR Upon DNA Damage, Which Blocks Its Degradation by the SCF skp2 Proteasome, Leading to Its Accumulation That Directly Inhibits DNA Replication.

AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines

The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma.

Impact of FDG-PET Imaging Versus Conventional Staging Modalities on Staging and Treatment Decisions in Large B-Cell, Follicular, and Hodgkin’s Lymphomas.

Effects of the Indazolylpyrimidine GW786034 on Angiogenesis and MM Cell Growth: Therapeutic Implications.

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

Telomerase Regulation, Cell Cycle, and Telomere Stability in Primitive Hematopoietic Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only